SCHEMBL2825992

SCHEMBL2825992

C[N+](C)(C)CCOP(=O)([O-])Oc1ccc(N)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.45
AKT1 P31749 2/20 0.45
ESR1 P03372 1/20 0.45
ADORA3 P0DMS8 1/20 0.45
CDC25A P30304 1/20 0.45
AGTR1 P30556 1/20 0.45
ADRA1A P35348 1/20 0.45
KCNH2 Q12809 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.42
CA12 O43570 2/20 0.36
CA1 P00915 2/20 0.36
CA2 P00918 2/20 0.36
CA4 P22748 2/20 0.36
CA5A P35218 2/20 0.36
CA7 P43166 2/20 0.36
CA9 Q16790 2/20 0.36
CA5B Q9Y2D0 2/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
PRKD3 O94806 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19244145 0.86 LMNA (0.46) LMNAAKT1ESR1ADORA3CDC25A
SCHEMBL8154893 0.84 LMNA (0.47) LMNAAKT1ESR1ADORA3CDC25A
SCHEMBL9680162 0.82 ALDH1A1 (0.40) LMNAAKT1ESR1ADORA3CDC25A
SCHEMBL549432 0.81 CA1 (0.54) LMNAAKT1ESR1ADORA3CDC25A
SCHEMBL19244142 0.81 PKM (0.43) LMNAAKT1ESR1ADORA3CDC25A
SCHEMBL19244141 0.79 MAPT (0.51) LMNAAKT1ESR1ADORA3CDC25A
SCHEMBL19749284 0.79 SMN1; SMN2 (0.44) LMNAAKT1ESR1ADORA3CDC25A
SCHEMBL8601761 0.77 ITGB3 (0.48) LMNAKCNH2SMN1; SMN2MEN1KMT2A
SCHEMBL14691027 0.77 LMNA (0.43) LMNAAKT1ESR1ADORA3CDC25A
SCHEMBL17746879 0.76 LMNA (0.57) LMNAAKT1ESR1ADORA3CDC25A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023066980-A1 4-AMINOPHENYLPHOSPHORYLCHOLINE COMPOUNDS FOR BLOCKING C-REACTIVE PROTEIN PENTRACOR GMBH (DE) 2023-04-27 WO claimed
EP-4169577-A1 4-AMINOPHENYLPHOSPHORYLCHOLINE COMPOUNDS FOR THE INHIBITION OF C-REACTIVE PROTEIN Pentracor GmbH (DE) 2023-04-26 EP claimed
EP-2713163-B1 Methods for isolating vesicles SAMSUNG ELECTRONICS CO LTD (KR) 2019-05-08 EP claimed
US-9310315-B2 Methods for detecting defects in inorganic-coated polymer surfaces Life Technologies Corporation (US) 2016-04-12 US claimed
EP-2554975-A1 Method and substrate for detecting defects in inorganic-coated polymer surfaces Life Technologies Corporation (US) 2013-02-06 EP claimed
US-8304242-B2 Methods for detecting defects in inorganic-coated polymer surfaces Life Technologies Corporation (US) 2012-11-06 US claimed
CN-102164957-A Methods and compositions for discovery of target-specific antibodies using antibody repertoire array (ARA) THERACLONE SCIENCES 2011-08-24 CN claimed
CN-121673815-A Flame-retardant nylon 66 material and preparation method thereof 安徽昊源化工集团有限公司 2026-03-17 CN disclosed
US-20250333849-A1 SOLVENT-BASED COMPOSITIONS AND RELATED METHODS FOR MOLYBDENUM ETCHING ENTEGRIS INC (US) 2025-10-30 US disclosed
US-12350308-B2 Phosphorylcholine conjugates and uses thereof TPCERA LTD. (IL) 2025-07-08 US disclosed
CN-119978772-A Foaming material for polyurethane material and preparation method and application thereof 山东商润润滑油有限公司 2025-05-13 CN disclosed
CN-115052677-B Use of alkali metal hydroxide solutions for regeneration of single-column columns 彭特科尔有限公司 2025-03-28 CN disclosed
US-20240400589-A1 4-AMINOPHENYLPHOSPHORYLCHOLINE COMPOUNDS FOR BLOCKING C-REACTIVE PROTEIN PENTRACOR GMBH (DE) 2024-12-05 US disclosed
WO-2009079571-A2 METHODS FOR DETECTING DEFECTS IN INORGANIC-COATED POLYMER SURFACES Life Technologies Corporation (US) 2009-06-25 WO disclosed
EP-0512905-B1 Heterobifunctional antibodies possessing both catalytic and specific antigen binding properties and methods using them PASTEUR SANOFI DIAGNOSTICS (FR) 1997-10-29 EP disclosed
US-5665347-A TREATING AUTOIMMUNE DISEASES GENETICS INSTITUTE (US) 1997-09-09 US disclosed
WO-1996023521-A1 IL-12 INHIBITION OF B1 CELL ACTIVITY MEDICAL COLLEGE OF OHIO (US) 1996-08-08 WO disclosed
US-5367058-A Modified antibodies with increased affinity BECTON, DICKINSON AND COMPANY (US) 1994-11-22 US disclosed
EP-0512905-A2 Heterobifunctional antibodies possessing both catalytic and specific antigen binding properties and methods using them PASTEUR SANOFI DIAGNOSTICS (FR) 1992-11-11 EP disclosed
US-5003065-A Phosphorus-containing Benzo Crown Ethers STATE UNIVERSITY OF NEW YORK, STATE UNIVERSITY PLAZA, A CORP OF NY. 1991-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240400589-A1 4-AMINOPHENYLPHOSPHORYLCHOLINE COMPOUNDS FOR BLOCKING C-REACTIVE PROTEIN C3AR1, S100P, PCTP LMNA 3339/4885AKT1 3561/4885ESR1 4129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.